Citigroup Inc Lyell Immunopharma, Inc. Transaction History

Citigroup Inc

$169 Billion
Q3 2024

A detailed history of Citigroup Inc transactions in Lyell Immunopharma, Inc. stock. As of the latest transaction made, Citigroup Inc holds 129,303 shares of LYEL stock, worth $78,874. This represents 0.0% of its overall portfolio holdings.

Number of Shares

129,303

Previous 49,347 162.03%

Holding current value

$78,874

Previous $71,000 150.7%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$1.13 - $1.88 $90,350 - $150,317	79,956 Added 162.03%	129,303 $178,000
Q2 2024 Aug 12, 2024	BUY	$1.3 - $3.01 $2,158 - $4,996	1,660 Added 3.48%	49,347 $71,000
Q1 2024 May 10, 2024	SELL	$1.71 - $3.07 $47,974 - $86,128	-28,055 Reduced 37.04%	47,687 $106,000
Q4 2023 Feb 09, 2024	SELL	$1.39 - $2.35 $164,015 - $277,292	-117,997 Reduced 60.91%	75,742 $146,000
Q3 2023 Nov 09, 2023	BUY	$1.45 - $3.35 $46,726 - $107,953	32,225 Added 19.95%	193,739 $284,000
Q2 2023 Aug 10, 2023	SELL	$1.89 - $3.86 $482,352 - $985,122	-255,213 Reduced 61.24%	161,514 $513,000
Q1 2023 May 11, 2023	BUY	$1.97 - $3.58 $287,771 - $522,955	146,077 Added 53.97%	416,727 $983,000
Q4 2022 Feb 09, 2023	BUY	$2.78 - $8.09 $177,875 - $517,630	63,984 Added 30.96%	270,650 $939,000
Q3 2022 Nov 10, 2022	BUY	$5.54 - $8.27 $967,616 - $1.44 Million	174,660 Added 545.71%	206,666 $1.51 Million
Q2 2022 Aug 10, 2022	SELL	$3.68 - $6.8 $35,460 - $65,524	-9,636 Reduced 23.14%	32,006 $208,000
Q1 2022 May 12, 2022	SELL	$5.05 - $7.7 $29,517 - $45,006	-5,845 Reduced 12.31%	41,642 $210,000
Q4 2021 Feb 10, 2022	BUY	$7.13 - $15.19 $319,374 - $680,405	44,793 Added 1662.69%	47,487 $368,000
Q3 2021 Nov 10, 2021	BUY	$11.0 - $17.95 $29,634 - $48,357	2,694 New	2,694 $40,000

Others Institutions Holding LYEL

# of Institutions

121

Shares Held

142M

Call Options Held

18.1K

Put Options Held

200

View Full List

About Lyell Immunopharma, Inc.

Ticker LYEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 247,824,992
Market Cap $151M
Description
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...

More about LYEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account